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Abstract
Background
Current National Comprehensive Cancer Network guidelines recommend postoperative
radiation therapy based only on adverse pathologic findings (APFs), irrespective of preop-
erative risk group. We assessed whether a model incorporating both the preoperative risk
group and APFs could predict long-term oncologic outcomes better than a model based on
APFs alone.
Methods
We retrospectively reviewed 4,404 men who underwent radical prostatectomy (RP) at our
institution between 1992 and 2014. After excluding patients receiving neoadjuvant therapy
or with incomplete pathological or follow-up data, 3,092 men were included in the final anal-
ysis. APFs were defined as extraprostatic extension (EPE), seminal vesicle invasion (SVI),
or a positive surgical margin (PSM). The adequacy of model fit to the data was compared
using the likelihood-ratio test between the models with and without risk groups, and model
discrimination was compared with the concordance index (c-index) for predicting biochemi-
cal recurrence (BCR) and prostate cancer-specific mortality (PCSM). We performed multi-
variate Cox proportional hazard model and competing risk regression analyses to identify
predictors of BCR and PCSM in the total patient group and each of the risk groups.
Results
Adding risk groups to the model containing only APFs significantly improved the fit to the
data (likelihood-ratio test, p <0.001) and the c-index increased from 0.693 to 0.732 for BCR
and from 0.707 to 0.747 for PCSM. A RP Gleason score (GS)8 and a PSM were indepen-
dently associated with BCR in the total patient group and also each risk group. However,
only a GS8 and SVI were associated with PCSM in the total patient group (GS8: haz-
ard ratio [HR] 5.39 and SVI: HR 3.36) and the high-risk group (GS8: HR 6.31 and SVI:
HR 4.05).
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Conclusion
The postoperative estimation of oncologic outcomes in men with APFs at RP was improved
by considering preoperative risk group stratification. Although a PSM was an independent
predictor for BCR, only a RP GS8 and SVI were associated with PCSM in the total patient
and high-risk groups.
Introduction
Prostate cancer (PC) has become the most common non-dermatologic cancer amongWestern
men.[1] Due to prostate-specific antigen (PSA) screening efforts, increasing numbers of PC
cases are diagnosedwhen the tumor is still confined to the prostate.[2] The prolonged natural
history of the disease as well as the potential risk of progression into metastasis and death must
be taken into consideration during the initial management of newly-diagnosedPC. The initial
evaluation, including serumPSA level, biopsy Gleason score (GS), and clinical T staging, deter-
mines risk stratification and assists in treatment decision-making. Several risk group stratifica-
tions, such as the D'Amico and National Comprehensive Cancer Network (NCCN), have been
constructed to predict the oncologic outcome in patients with PC, and initial therapy for non-
metastatic PC is determined according to these risk group stratifications.[3, 4]
Radical prostatectomy (RP) is one of the most commonly used treatments for patients with
localizedPC and a life expectancy of10 years. However, approximately 30% of patients
treated with RP have adverse pathologic findings (APFs).[5] Post-RP recurrence rates in
patients with APFs may be greater than 60% at 5 years.[6] The American Urological Associa-
tion (AUA) and American Society for RadiationOncology (ASTRO) recommend that adjuvant
radiotherapy (ART) should be offered for these patients with APFs because this therapy has
been demonstrated to reduce biochemical recurrence (BCR), local recurrence, and clinical pro-
gression.[7] However, for the decision to administer ART is based only on the presence of
APFs at RP, irrespective of preoperative risk group stratification.[8]
We hypothesized that the oncologic risk associated with APFs is highly influenced by the
preoperative risk group of the patient. Therefore, we assessed whether a model incorporating
the preoperative risk group and APFs can predict the long-term oncologic outcomes better
than that based only on APFs.
Materials and Methods
Patient population
After Institutional ReviewBoard approval was obtained, we performed a retrospective review
of the data collected from our PC database on 4,404 patients who had undergone RP at our
institution between 1992 and 2014. After exclusion of patients who received neoadjuvant ther-
apy and those with incomplete pathological or follow-up data, 3,092 men were included in the
final analysis. Patients with lymph node invasion at RP were excluded because they were candi-
dates for adjuvant androgen deprivation therapy rather than ART.
Patient characteristics
Clinical characteristics of the patients, including age, preoperative PSA level, clinical stage, and
biopsy GS, were obtained through a review of our institutional medical records. TNM stage
was determined according to the American Joint Committee on Cancer 7th edition TNM stag-
ing system.[9] All patients were stratified into low-, intermediate-, and high-risk groups
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according to the 2015 Prostate Cancer NCCNGuidelines Version 1.[4] APFs were defined as
extraprostatic extension (EPE), seminal vesicle invasion (SVI), or a positive surgical margin
(PSM).[7]
Pathological analysis
As describedpreviously, pathological analysis of RP specimens was performed by an experienced
uropathologist at our institute.[10] Briefly, the entire surface of the resected prostate specimens
was coated with India ink, fixed in neutral buffered formalin, and embedded in paraffin blocks.
Whole-mount step sectionswere cut transversely at regular intervals from the apex of the pros-
tate to the tips of the seminal vesicles. Each sectionwas examined for SVI, EPE, and PSM.
Follow-up
A postoperative PSA follow-up was undertaken at 3-month intervals for the first 2 years and at
6-month intervals for the next 3 years; an annual PSA follow-up was recommended thereafter.
Administration of adjuvant or salvage radiotherapy (SRT) was at the discretion of the surgeon.
BCRwas defined as any two consecutive increases in serumPSA0.2 ng/ml after RP. Bio-
chemical recurrence–free survival (BCRFS)was defined as the time from the RP to the occur-
rence of BCR.Data regarding mortality and cause of death were obtained frommedical records
in the Cancer RegistryCenter database at our institution.[11] PC-specificmortality (PCSM)
was designated when the underlying cause of death was PC or the patient had castration-resis-
tant PC at the time of death.
Statistical analysis
Baseline characteristics of men and pathologic outcomes were compared using χ2-tests for cate-
gorical data, and Student’s t-test or analysis of variance (ANOVA) test for continuous data. The
adequacy of model fit to the data was compared between the models of APFs with and without
risk groups using the likelihood-ratio test. Discriminationwas compared using concordance
index (c-index) for predicting BCR and PCSM.[12] The c-index is similar to an area under the
receiver operating characteristic curve and is applicable to time-to-event data.[13] It values can
range from 0.5, which indicates no predictive discrimination, to 1.0, which denotes a perfect sepa-
ration of patients with different outcomes.[14] The Kaplan-Meier methodwith a log-rank test
was used to estimate and compare the probabilities of BCR between groups. Cox proportional
hazard models were used to investigate associations between variables and the risk of BCR.
The cumulative incidence estimates of PCSMwere compared between the groups using Gray's
modified log-rank test for PCSM. To account for potential causes of death other than PC, a multi-
variate competing risk regression was also used to evaluate a possible association between the
covariates and the risk of PCSM.[15] Covariates consisted of patient age (continuous), year of sur-
gery (continuous), preoperative PSA level (continuous), RP GS (6, 7, and8), RP T stage (OC,
EPE, and SVI), PSM (categorical). Significant variables on univariate analysis were included in
the multivariate model. The statistical analysis was conducted using Stata v.12.0 (StataCorp, Col-
lege Station, TX,USA) and R (R version 3.0.1, R Foundation for Statistical Computing, Vienna,
Austria). Comparisons with p values<0.05 were considered to be statistically significant.
Results
Descriptive statistics
Of 3,092 patients in the final cohort, 603 (19.5%), 1,031 (33.3%), and 1,458 (47.2%) patients
were classified as low-risk, intermediate-risk, and high-risk groups, respectively, according to
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the NCCN risk stratification. Clinical and pathological features of all patients, stratified by pre-
operative risk group, are detailed in Table 1. There were significant differences in age, preoper-
ative PSA level, biopsy GS, clinical stage, and APFs across the risk groups (p<0.001 for all).
Comparison of the survival models’ performance
Table 2 shows comparison of the survivalmodels’ performance between the twomodels of APFs
with and without the preoperative risk group for BCR and PCSM. Adding preoperative risk
groups to the model significantly improved the fit to the data for BCR and PCSM (likelihood-
ratio test p<0.001 for both). The c-index also showed that the predictive value for BCR and
PCSM increased considerably when the preoperative risk classification was incorporated into the
model with APFs (c-index for BCR from 0.693 to 0.732 and for PCSM from 0.707 to 0.747).
Table 1. Comparison of clinical and pathological characteristics according to preoperative risk group.
Preoperative risk group
Variable Total Low Intermediate High p value*
3,092 (100) 603 (19.5) 1,031 (33.3) 1,458 (47.2)
Age, years <0.001**
Median 66 64 65 66
IQR 61–70 59–69 61–70 62–71
Year of surgery 0.050**
Median 2009 2009 2009 2010
IQR 2007–2011 2007–2011 2007–2011 2008–2011
PSA, ng/ml <0.001**
Median 8.0 5.6 8.1 11.3
IQR 5.3–13.9 4.4–7.0 5.3–12.0 6.5–23.4
Biopsy GS <0.001***
6 1,386 (44.8) 603 (100) 444 (43.1) 339 (23.3)
7 980 (31.7) 0 587 (56.9) 393 (27.0)
8 726 (23.5) 0 0 726 (49.7)
Clinical T stage <0.001***
T2 2,145 (69.4) 603 (100) 1031 (100) 555 (38.1)
T3 947 (30.6) 0 0 903 (61.9)
RP GS <0.001***
6 865 (28.0) 371 (61.5) 297 (28.8) 197 (13.5)
7 1,533 (49.6) 208 (34.5) 643 (62.4) 682 (46.8)
8 694 (22.4) 24 (4.0) 91 (8.8) 579 (39.7)
RP T stage <0.001***
OC 1,343 (43.4) 380 (63.0) 505 (49.0) 458 (31.4)
EPE 1,448 (46.8) 211 (35.0) 485 (47.0) 752 (51.6)
SVI 301 (9.8) 12 (2.0) 41 (4.0) 248 (17.0)
PSM <0.001***
No 1,604 (51.9) 400 (66.3) 546 (53.0) 658 (45.1)
Yes 1,488 (48.1) 203 (33.7) 485 (47.0) 800 (54.9)
IQR = interquartile range; PSA = prostate-specific antigen; GS = Gleason score; RP = radical prostatectomy; OC = organ confined; EPE = extraprostatic
extension; SVI = seminal vesicle invasion; PSM = positive surgical margin.
* p values are for comparison of low, intermediate, and high risk groups.
** p value derived from analysis of variance model.
*** p value derived from Pearson’s χ2-test.
doi:10.1371/journal.pone.0164497.t001
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Cox regression analysis of biochemical recurrence
Of 3,092 patients, 899 men had experiencedBCR at a median follow-up of 66 months. The
BCRFS rate for men with APFs was worse than those without APFs in not only the total patient
group but also in each risk group (total: p<0.001, low: p = 0.027, intermediate: p<0.001, and
high: p<0.001; Fig 1A, 1B, 1C and 1D, respectively).
Table 3 shows the results of themultivariate Cox regression analyses predicting BCR following
RP in all patients and the stratified cohort according to the preoperative risk group. For the total
patient group, the year of surgery (hazard ratio [HR] 0.97, p<0.001), PSA (HR 1.00, p = 0.012),
RP GS (GS 7: HR 2.18, p<0.001 vs. GS8: HR 4.66, p<0.001), and APFs (EPE: HR 1.36,
p<0.001; SVI: HR 2.45, p<0.001; and PSM: HR 1.93, p<0.001) were significantly associated
with BCR. In the low-risk group, age (HR 1.04, p = 0.029), year of surgery (HR 0.85, p<0.001),
RP GS8 (HR 2.94, p = 0.007), and PSM (HR 1.87, p<0.010) were independent prognostic fac-
tors for BCR,while in the intermediate-risk group, BCRwas significantly associatedwith PSA
(HR 1.08, p<0.001), RP GS (GS 7: HR 1.73, p = 0.004 vs. GS8: HR 1.85, p = 0.022), and APFs
(SVI: HR 2.16, p = 0.002; PSM: HR 2.42, p<0.001). For the high-risk group, year of surgery
(HR 0.98, p = 0.022), PSA (HR 1.00, p<0.001), RP GS (GS 7: HR 2.35, p<0.001 vs. GS8: HR
4.63, p<0.001), and APFs (EPE: HR 1.51, p<0.001; SVI: HR 2.34, p<0.001; and PSM: HR 1.71,
p<0.001) were significant predictors for BCR.EPE was not an independent prognostic factor of
BCR for the low- and intermediate-risk groups (p = 0.910 and p = 0.923, respectively). There was
also no association between SVI and BCR in the low-risk group (p = 0.118).
Competing risk regression analysis of prostate cancer-specific mortality
Of 3,092 patients, 85 men (low: 8, intermediate: 13, and high: 63) died due to PC. The cumula-
tive incidence estimates of PCSM for men with APFs was higher than those without APFs in
not only the total patient group but also the high-risk group (Gray’s modified log rank,
p = 0.001 and p = 0.010, respectively), while the estimate was not elevated in the low- and inter-
mediate-risk groups (p = 0.903 and p = 0.253, respectively; Fig 2).
In the multivariate competing risk regression analysis, RP GS8 and SVI were independent
predictors for PCSM in the total patient group (GS8: HR 5.50, p<0.001; SVI: HR 3.02,
p = 0.002) and the high-risk group (GS8: HR 6.21, p = 0.011; SVI: HR 3.46, p = 0.005), while
EPE and PSM were not (Table 4).
Discussion
Approximately 60% of patients with APFs after RP will experience BCR.[6] In this context, the
AUA/ASTRO guideline recommends ART to patients with APF at RP and SRT to patients
Table 2. Comparison of the Survival Models’ Performance.
Survival model
APFs APFs + Preoperative risk group
c-index
BCR 0.693 0.732
PCSM 0.707 0.747
Likelihood-ratio test
BCR p < 0.001
PCSM p < 0.001
APF = adverse pathologic findings; c-index = concordance index; BCR = biochemical recurrence;
PCSM = prostate cancer-specific mortality.
doi:10.1371/journal.pone.0164497.t002
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with biochemical or local recurrence after RP in whom there is no evidence of distant meta-
static disease through an in-depth discussion of possible side effects of radiotherapy as well as
the potential benefits of preventing recurrence.[7] The AUA/ASTRO guideline for ART is
largely based on three randomized clinical trials (SWOG 8794, EORTC 22911, and ARO 96–
02).[16–18] These randomized clinical trials have shown that ART after RP reduces the risk of
BCR for patients with APFs. In addition, SWOG 8794 reported improved overall survival with
ART compared to observation alone.
Even though this guideline is in place, clinicians differ in their opinions and practice with
regards to the provision of ART.[19] This variability is partly due to a risk of functional compli-
cations such as incontinence and impotence while the oncological benefit may not be clinically
Fig 1. Kaplan-Meier estimates of biochemical recurrence–free survival (BCRFS) after radical prostatectomy (RP) by the presence of
adverse pathological findings (APFs) for (A) total (log-rank test, p <0.001), (B) low-risk (p = 0.027), (C) intermediate-risk (p <0.001), and
(D) high-risk (p <0.001) patients.
doi:10.1371/journal.pone.0164497.g001
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significant.[20] The SWOG 8794 trial reported that patients who underwent SRT after BCR
had a similar overall survival rate compared to those who underwentART with an undetectable
PSA level after RP.[21] Soloway et al. reported that patients with a PSM who underwent ART
and recurred had similar long-term outcomes compared to those who underwent SRT after
BCR.[22] These results suggest that ART is not necessary for all patients with APFs after RP.
Kang et al. subsequently evaluated patients with APFs whomeet the current AUA/ASTRO
guideline for ART. They found that only 16.6% of ART patients developed BCR. In addition, in
87 patients with a preoperative PSA<6.35 ng/ml and a GS<8, only three were recurred
(3.4%). Thus, they recommended a more customized approach to selecting patients for ART to
avoid significant overtreatment.[23] Swanson et al. also concluded that the risk of BCR in men
with locally advanced disease varies widely depending on the preoperative PSA value (<10 vs.
10 ng/ml) and RP GS (<7 vs.7).[5]
NCCN preoperative risk group stratification has been widely adopted as a mainstay of treat-
ment criteria prior to making a definitive treatment. Extending its usefulness and the signifi-
cance of preoperative risk group stratification to post-RP patients with APFs would be
reasonable. Based on this hypothesis, we believed that preoperative risk group stratification
may also influence oncologic risk associated with APFs and could play an adjunctive role in the
selection of optimal candidates for ART after RP. Therefore, we assessed whether a model
incorporating preoperative risk and APFs could predict long-term oncologic outcomes better
than that based only on APFs.
Imnadze et al. recently reported that the risk of BCR in men with APFs is dramatically
attenuated by a low preoperative risk status, which reduces the risk associated with findings
such as ECE or high (>50%) Gleason grade disease. This finding suggests that preoperative
risk group stratification is an important factor to consider when evaluating the post-RP risk of
BCR in the context of APFs.[8] However, this study was limited by its use of only BCR as an
end-point.
Table 3. Multivariate Cox regression analysis of biochemical recurrence according to preoperative risk group.
Preoperative risk group
Variable Total Low Intermediate High
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age, years 1.01 (0.99–1.02) 0.093 1.04 (1.00–1.08) 0.029
Year of surgery 0.97 (0.95–0.98) <0.001 0.85 (0.79–0.91) <0.001 0.97 (0.94–1.02) 0.305 0.98 (0.95–0.99) 0.022
PSA, ng/ml 1.00 (1.00–1.00) 0.012 1.09 (0.96–1.24) 0.170 1.08 (1.05–1.11) <0.001 1.00 (1.00–1.01) <0.001
RP GS
6 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref)
7 2.18 (1.74–2.72) <0.001 1.60 (0.97–2.68) 0.067 1.73 (1.20–2.50) 0.004 2.35 (1.59–3.48) <0.001
8 4.66 (3.70–5.88) <0.001 2.94 (1.34–6.48) 0.007 1.85 (1.09–3.12) 0.022 4.63 (3.15–6.82) <0.001
RP T stage
OC 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref)
EPE 1.36 (1.14–1.61) <0.001 0.97 (0.57–1.65) 0.910 1.02 (0.75–1.37) 0.923 1.51 (1.20–1.91) <0.001
SVI 2.45 (1.97–3.04) <0.001 2.23 (0.82–6.10) 0.118 2.16 (1.32–3.53) 0.002 2.34 (1.79–3.06) <0.001
PSM
No 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref)
Yes 1.93 (1.66–2.24) <0.001 1.87 (1.16–3.03) 0.010 2.42 (1.79–3.28) <0.001 1.71 (1.42–2.06) <0.001
PSA = prostate-specific antigen; RP = radical prostatectomy; GS = Gleason score; OC = organ confined; EPE = extraprostatic extension; SVI = seminal
vesicle invasion; PSM = positive surgical margin; HR = hazard ratio; CI = confidence interval.
Significant variables on univariate analysis were included in the multivariate model.
doi:10.1371/journal.pone.0164497.t003
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In our present study, we showed the additive prognostic value of preoperative risk group
stratification for postoperative oncologic outcomes in patients with APFs. We demonstrated
that APFs at RP are associated with an increased risk of BCR and PCSM, but this oncologic
risk is highly influenced by preoperative risk group. A PSM, which has been a common indica-
tion for ART, was independently associated with BCR in not only the total patient group but
also each of the risk groups, while RP GS8 and SVI were associated with PCSM in the total
patient and the high-risk groups. These findings suggest that additional stratification by preop-
erative risk group can more accurately predict oncological outcomes of patients with APFs.
This study has several limitations. First, all data were reviewed retrospectively from a single
institution; therefore, our results may not be generalizable. Second, information about adjuvant
Fig 2. Cumulative incidence estimates of prostate cancer-specific mortality (PCSM) after radical prostatectomy (RP) using a
competing risk analysis by adverse pathological findings (APFs) for (A) total (Gray’s modified log rank, p = 0.001), (B) low-risk
(p = 0.903), (C) intermediate-risk (p = 0.253), and (D) high-risk (p = 0.010) patients.
doi:10.1371/journal.pone.0164497.g002
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or salvage therapy was not included in the analysis because only a fewmen received ART and
because salvage therapy can act as a surrogate marker of BCR.[24, 25] Finally, a major limita-
tion was that we did not perform a competing risk analysis for PCSM in the low- and interme-
diate-risk groups because of the small number of events. To better assess the effect of
preoperative risk group on these groups, a larger sample size and longer follow-up will be
required.
Conclusions
Our results show that the postoperative estimation of oncologic outcomes in men with APFs at
RP is improved by considering preoperative risk group stratification. Although a PSM was an
independent predictor for BCR, only an RP GS8 and SVI were associated with PCSM in the
total patient and high-risk groups. These findings suggest that preoperative risk group stratifi-
cation should be considered in the selection of optimal ART candidates after RP, although our
present results need to be validated by future studies before making a recommendation.
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